TATFAR’s 2018 meeting: Live streaming of 7 Mar opening session

Dear All: On 7-9 Mar 2018, the Transatlantic Task Force on Antimicrobial Resistance (TATFAR) will meet in Atlanta, GA to discuss:

  • Improving antibiotic use in humans and animals,
  • Preventing infections and their spread, and
  • Strengthening the drug pipeline.

The opening session (8.30-10.00a EST on 7 Mar) will be available for viewing via live-streaming

What is TATFAR? Created in 2009, TATFAR comprises AMR-focused government-level experts from Canada, the European Union (EU), Norway, and the United States. CDC maintains the secretariat for the group. TATFAR is currently working on implementation of a set of policy recommendations that span antibiotic use (human & veterinary), infection prevention, and strategies for improving the pipeline of new therapeutic options.

There’s no public agenda for the full meeting, but I infer that the focus is on reviewing progress to date and the need for any updates to TATFAR’s current policy recommendations. It’s great to see our government partners maintaining steady effort on the important problem of antimicrobial-resistant infections!

Why does a meeting of TATFAR matter? As a lot of the needed change requires government-level action, having a knowledgeable and engaged government-based effort is critical for any progress. No, we don’t yet have the drugs we need — but we do have a lot of push incentives, a growing pipeline of both traditional and non-traditional products, and a supportive regulatory environment. No, we don’t yet have pull incentives — but the recent DRIVE-AB reports plus the prior work of the UK AMR Review and the Duke-Margolis project on incentives are driving substantive conversations on both sides of the Atlantic.

In short, the very existence of this group is one of many positive signs in this space. I hope you can make time to dial-in to get a feel for what our government-based colleagues are doing. My own view is that the overall trajectory gives hope that we may yet have the tools needed for ourselves, our children, and our grandchildren.

Many thanks to all who engaged with making this happen! All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Upcoming meetings of interest to the AMR community:

Share

WHO Bacterial Priority Pathogen List (PPL): 2024 update

Dear All, WHO have just released a 2024 update to their 2017 (bacterial) Priority Pathogen List (PPL)! Here are the links you need: The WHO 2024 PPL. WHO’s webpage about the 2024 PPL. A PowerPoint (.pptx) deck (and there is also a .pdf version) summarizing the new PPL and all prior PPLs. https://amr.solutions/pathogens-and-pipelines/, the AMR.Solutions webpage

Environmental, Animal, and Human Uses of Phage: WHO webinars

Dear All, I have just this weekend learned of a 3-part WHO webinar series on uses of phage. Two of the webinars have already been held; the 3rd is scheduled for 16 May. All are / will be available for post-webinar review. The links you need are below — in addition, a copy of the

New UK 5-year AMR plan: Subscription model details!

Dear All, Today is a newsletter double-header! Coming hard on the heels of the opportunity to support an ESCMID petition to UNGA 2024, the UK today released the details of its next five-year action plan. Excitingly for this audience, there is an updated roadmap for the UK’s next steps in its subscription model. Here are

ESCMID’s UNGA 2024 Petition to EU Health Ministers: Sign and Send!

Dear All, During the GLG AMR (Global Leaders Group for AMR) event just before ECCMID (see the 3 May 2024 newsletter entitled “Path To UNGA 2024 As Of 3 May 24 / Events On 14-15 May (DC, NYC)” for details), ESCMID leadership announced that ESCMID had developed a petition to be sent by and from the

Scroll to Top